Clinical trial NCT03849365: Study of Erectile Dysfunction, Urinary Incontinence and Related QoL After TOOKAD® VTP for Low Risk Prostate Cancer
Official title: Study of Erectile Dysfunction, Urinary Incontinence and Related Quality of Life After TOOKAD® Vascular Targeted Photodynamic Therapy (VTP) for Minimally Invasive Treatment of Unilateral Low Risk Prostate Cancer
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Low Risk Prostate Cancer
Lead sponsor: Steba Biotech S.A.
Sponsor class: OTHER
Collaborators: name: International Drug Development Institute
name: PrimeVigilance Ltd., UK
First posted: 2019-02-21
Enrollment: 23
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Multiple center, single-arm, open-label, 12-month follow-up phase IV pragmatic clinical trial.
Primary purpose: TREATMENT

Brief summary: Multiple center, single-arm, open-label, 12-month follow-up phase IV pragmatic clinical trial in men with unilateral prostate cancer meeting eligibility criteria for the drug (as per the European Economic Area (EEA) Marketing Authorisation) to assess the occurrence and dynamics of the time with toxicities (urinary incontinence Grade 2 and over and/or erectile dysfunction Grade 2 and over) in patients 12 months following TOOKAD® VTP.

Detailed description: This is a multiple center, single-arm, open-label, 12-month follow-up phase IV pragmatic clinical trial. Men with unilateral prostate cancer meeting eligibility criteria for the drug (as per the EEA Marketing Authorisation) will receive TOOKAD® VTP under general anesthesia. The primary objective is to assess the occurrence and dynamics of the time with toxicities (urinary incontinence Grade 2 and over and/or erectile dysfunction Grade 2 and over) in patients 12 months following TOOKAD® VTP. Prior to the TOOKAD® VTP, patients will undergo routine ultrasound examination in the operating room for morphometric description of the prostate and to facilitate accurate treatment guidance for the treatment with TOOKAD® VTP. Treatment will then be applied to the prostate gland as a hemi-ablation procedure designed to destroy the lobe of the prostate gland that contains the cancer. Afterwards, patients will be followed for 12 months with clinical evaluation, data collection on erectile and urinary functions at 1, 2, 3 6 and 12 months, using the Expanded Prostate Cancer Index Composite (EPIC), International Index of Erectile Function (IIEF) and International Prostate Score Symptom (IPSS) questionnaires on Quality Of Life (QOL) and Prostate Specific Antigen (PSA) testing at 3, 6 and 12 months.

The clinical follow-up of patients will follow local standard of care processes, based on recommendations in the European Summary of Product Characteristics (SmPC).

This study is a phase IV pragmatic trial using optimal dose of TOOKAD® and optimal light-energy level conditions that were determined during development and approved by the European Commission.

Eligibility criteria: Inclusion Criteria:

* Men over 18 years of age with a life expectancy ≥ 10 years

  -.Unilateral adenocarcinoma of the prostate accurately located and confirmed as unilateral using high resolution biopsy strategies based on current best practice, such as multi- parametric MRI based strategies or template-based biopsy procedures.
* Clinical stage T1c or T2a,
* Gleason Score ≤ 6, based on high-resolution biopsy strategies
* 3 positive cancer cores with a maximum cancer core length of 5 mm in any one core or 1 -2 positive cancer cores with ≥ 50 % cancer involvement in any one core or a PSA density ≥ 0.15 ng/mL/cm3.
* PSA ≤ 10 ng/mL
* If the patient is sexually active with women who are capable of getting pregnant, he and/or his partner should use an effective form of birth control to prevent getting pregnant during a period of 90 days after the VTP procedure.
* Signed Informed Consent Form

Exclusion Criteria:

GENERAL EXCLUSION CRITERIA :

* Unwillingness to accept the treatment;
* Any previous prostatic interventions where the internal urinary sphincter may have been damaged, including trans-urethral resection of the prostate (TURP) for benign prostatic hypertrophy.
* Participation in another clinical study involving an investigational product within 1 month before study entry;
* Inability to understand the informed consent document, to give consent voluntarily or to complete the study tasks, especially inability to understand and fulfill the health-related QOL questionnaire;
* Subjects in custody and or residing in a nursing home or rehabilitation facility;
* Biopsy proven locally advanced or metastatic prostate cancer.

SURGERY AND OTHER TREATMENT-RELATED CONDITIONS OF EXCLUSION

* Any condition or history of illness or surgery that in the opinion of the investigator might affect the conduct and results of the study or pose additional risks to the subject or any medical condition that precludes the administration of a general anaesthetic or invasive procedures.
* Hypersensitivity to the active substance or to the excipient (mannitol)
* Current or prior treatment for prostate cancer.
* Patients who have been diagnosed with cholestasis.
* Current exacerbation of rectal inflammatory bowel disease.
* Anticoagulant medicinal products and those that decrease platelet aggregation (e.g. acetylsalicylic acid) should be stopped at least 10 days before the procedure with TOOKAD. Medicinal products that prevent or reduce platelet aggregation should not be started for at least 3 days after the procedure.

Primary outcomes:
measure: Cumulated time with toxicity (duration)
timeFrame: 12 months
measure: Cumulated time with toxicity (prevalence)
timeFrame: 12 months
measure: Cumulated time with toxicity (area under the curve)
timeFrame: 12 months
Secondary outcomes:
measure: Time with erectile dysfunction (duration)
timeFrame: 12 months
measure: Time with erectile dysfunction (prevalence)
timeFrame: 12 months
measure: Time with erectile dysfunction (Area under the curve)
timeFrame: 12 months
measure: Time with urinary incontinence (duration)
timeFrame: 12 months
measure: Time with urinary incontinence (prevalence)
timeFrame: 12 months
measure: Time with urinary incontinence (Area under the curve)
timeFrame: 12 months
measure: Correspondence between results of EPIC and IIEF instruments
timeFrame: 12 months
measure: PSA density
timeFrame: 12 months
measure: Rate of Adverse Events
timeFrame: 12 months
measure: Time to resolution of Adverse events
timeFrame: 12 months
measure: Additional prostate cancer treatments
timeFrame: 12 months
measure: Extension of prostate cancer
timeFrame: 12 months
Other outcomes:
Locations:
city: Angers
country: France
facility: Centre Hospitalier Universitaire (CHU)
Study officials:
affiliation: Centre Hospitalier Universitaire (CHU) ANGERS
name: Abdel-Rahmène AZZOUZI, Professor
role: PRINCIPAL_INVESTIGATOR
References: